spacer spacer  
  spacer
 
spacer

 
spacer
 
Overview
underline
spacer
 

Nosocomial (hospital-acquired) infections continue to complicate the clinical course of critically ill patients and, consequently, to create substantial economic and human costs. These infections may lead to complications in approximately 30% of those patients admitted to an intensive care unit (ICU) and cost an estimated $25,000 per infection. Previous studies have shown that the administration of inadequate antimicrobial treatment of nosocomial infections is associated with a significantly higher mortality rate; therefore, new guidelines and evidence-based practices to prevent healthcare-associated infections have been developed to improve patient outcomes. Although healthcare providers are cognizant of measures to control infection, inconsistent application of these measures remains a concern in the ICU and surgical settings.

In this regional dinner meeting series, we will present up-to-date information on the risk of acquiring nosocomial infections, highlight the most common sites of these infections, and discuss new guidelines for preventing and controlling infections in the hospital population. The goals are to enhance the awareness and understanding of the risks for infections and encourage guideline-based application of infection control measures to promote more favorable outcomes for patients.

 
Webcast Activity
underline
spacer
 

Early and Adequate Therapy Improves Outcomes in Invasive Fungal InfectionsMarin H. Kollef, MD

Antibiotic Stewardship for the Treatment of Intra-abdominal InfectionsJohn E. Mazuski, MD, PhD

Question & Answer

 
Learning Objectives
underline
spacer
 

Upon the completion of this activity, the participant should be better able to:

  • IDENTIFY patients at risk for infections due to yeast and multiply resistant gram-negative and gram-positive pathogens.
  • DESCRIBE the epidemiology of fungal infections in the hospital population.
  • OUTLINE an approach to providing appropriate empiric therapy for fungal infections.
  • DESCRIBE the importance of selecting appropriate empiric antimicrobial therapy for patients with intra-abdominal infections to avoid inadequate treatment and excessively broad therapy.
  • EXPLAIN the utility of limiting duration of antimicrobial therapy in patients with intra-abdominal infections to circumvent complications.

 
CE Information
underline
spacer
 

INTENDED AUDIENCE – Infectious disease physicians, hospitalists, internal medicine physicians, critical care and intensive care physicians; infectious disease, critical care, and ICU nurses; fellows (surgical and medical); and hospital pharmacists, ICU pharmacists, and hospital formulary committee directors.

PHYSICIAN CONTINUING MEDICAL EDUCATION:
ACCREDITATION STATEMENT – This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM) and ASi M. PIM is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT – Postgraduate Institute for Medicine designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

PHARMACIST CONTINUING EDUCATION: This is a knowledge-based activity for pharmacists.
ACCREDITATION STATEMENT – Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

CREDIT DESIGNATION STATEMENT – Postgraduate Institute for Medicine designates this continuing education activity for a maximum of 1.5 contact hour(s) (0.15 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number – 0809-9999-09-151-H01-P)


DISCLOSURE OF CONFLICTS OF INTEREST – Postgraduate Institute for Medicine (PIM) assesses conflict of interest with its instructors, planners, managers and other individuals who are in a position to control the content of CE activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM is committed to providing its learners with high quality CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Name of Faculty or Presenter Reported Financial Relationship
Marin H. Kollef, MD Serving as a consultant for CR Bard, Inc,
Merck & Co, Inc, and Pfizer Inc; and receiving fees for non-CME services
received directly from CR Bard, Inc,
Kimberly-Clark Corporation, Merck & Co,
Inc, and Pfizer Inc.
Russell E. Lewis, PharmD, FCCPServing as a consultant for Astellas Pharma Inc and Merck & Co, Inc; receiving fees for
non-CME services received directly from
Enzon Pharmaceuticals, Merck & Co, Inc,
and Pfizer Inc; and doing contracted
research for Astellas Pharma Inc, Gilead
Sciences, Inc, and Merck & Co, Inc.
John E. Mazuski, MD, PhDServing as a consultant for Bayer, Ortho- McNeil Pharmaceuticals, Inc, Schering- Plough Corporation, and Wyeth; receiving fees for non-CME services received directly from Merck & Co, Inc, Ortho-McNeil Pharmaceuticals, Inc, Schering-Plough Corporation, and Wyeth; and doing contracted research for Eli Lilly and Company, Ortho-McNeil Pharmaceuticals, Inc, and Pfizer Inc.
Name of Planner or Manager Reported Financial Relationship
Chris Washburn, PhDHas no real or apparent conflicts of interest to report.
Melinda Castro

Has no real or apparent conflicts of interest to report.

Linda Graham, RN, BSN, BA, Jan Hixon,
RN, BSN, MA, Trace Hutchison, PharmD,
Julia Kirkwood, RN, BSN, and Jan Schultz,
RN, MSN, CCMEP

Have no real or apparent conflicts of interest to report.


DISCLOSURE OF UNLABELED USE – This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Postgraduate Institute for Medicine (PIM) and ASiM, and Merck & Co, Inc do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM,
ASiM, and Merck & Co, Inc. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

OFF-LABEL PRODUCT DISCUSSION – All faculty have indicated that they have not referenced unlabeled/unapproved uses of drugs or products.

RELEASE DATE – December 23, 2009.    EXPIRATION DATE – December 31, 2010.

ESTIMATED TIME TO COMPLETE THE ACTIVITY – 1.5 hours.

METHOD OF PARTICIPATION – There are no fees for participating and receiving CME credit for this activity. During the period December 23, 2009 through December, 2010, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the posttest by recording the best answer to each question in the answer key on the evaluation form; 4) complete the evaluation form.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better. Your statement of credit will be made available to you online.

ACTIVITY FORMAT – This educational activity is a webcast consisting of approximately 1.5 hours of clinical presentations and question-and-answer sessions.

SYSTEM REQUIREMENTS
  • DSL, Cable, or faster Internet connection
  • Internet Explorer 6.0 or newer Web Browser
  • Adobe Flash Player
  • 16-bit sound card
  • 24-bit true color video card
  • Windows 98 or newer
    Pentium or AMD Athlon K6 266 MHz processor or faster
  • Mac OS 9 or later
    PowerPC G3 233MHz processor or faster
  • 128 MB RAM

Step 1. Pre-test

Please complete the Pre-Test Activity before proceeding to the webcast.

 
Step 2. Webcast

 
Step 3. Post-test

 
 
spacer  
  spacer
Advanced Studies in Medicine © 2011 Contact Us
spacer  
spacer